*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Simcere Pharmaceutical Group Limited**
**先聲藥業集團有限公司**
*(Incorporated in Hong Kong with limited liability)*
**(Stock code: 2096)**

# VOLUNTARY ANNOUNCEMENT ENTERING INTO AN EXCLUSIVE LICENSE AGREEMENT WITH VIGONVITA FOR NEW INDICATIONS OF DEUTERATED REMDESIVIR HYDROBROMIDE

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on December 3, 2025, the Group entered into a license agreement (the "**Agreement**") with Vigonvita Life Science Co., Ltd. ("**Vigonvita**") in respect of new indications of Deuterated Remdesivir Hydrobromide. Pursuant to the Agreement, the Group will obtain exclusive rights to Deuterated Remdesivir Hydrobromide in the Greater China region for the treatment of respiratory syncytial virus ("**RSV**") infection and human metapneumovirus (HMPV) infection. This collaboration will further strengthen the Group's product deployment in the anti-infection area.

## ABOUT DEUTERATED REMDESIVIR HYDROBROMIDE

Deuterated Remdesivir Hydrobromide is an oral nucleoside antiviral candidate with broad-spectrum activity against RNA viruses, acting through the inhibition of viral RNA-dependent RNA polymerase (RdRp). The Phase II clinical trial in China evaluating Deuterated Remdesivir Hydrobromide for the treatment of RSV infection in infants and young children aged 1–24 months (the "**Clinical Study**") has been completed. Clinical results demonstrated that the Deuterated Remdesivir Hydrobromide dry suspension formulation showed favorable antiviral efficacy against RSV as well as a good safety profile. Based on the positive results of the Clinical Study, the Deuterated Remdesivir Hydrobromide dry suspension has been granted Breakthrough Therapy drug designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Previously, the Deuterated Remdesivir Hydrobromide tablet formulation received full approval in China for the treatment of mild-to-moderate COVID-19 in adult patients.

**ABOUT VIGONVITA**

Established in 2013, Vigonvita Life Sciences Co., Ltd. (2630.HK) is an innovation-driven biopharmaceutical company committed to improving patients' health and quality of life. Vigonvita is dedicated to the development of novel drugs in the fields of neuropsychiatry, reproductive health and viral infection. Vigonvita has established an integrated functional and fully internally controlled system covering the whole industrial chain from lead discovery for innovative drugs, druggability evaluation, preclinical and clinical research to manufacturing and commercialization, thereby enabling the rapid and efficient transformation of candidate drugs from laboratory research to clinical application.

**ABOUT THE COMPANY**

The Company is an innovation and R&D-driven pharmaceutical company and has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Company focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
**Simcere Pharmaceutical Group Limited**
**Mr. Ren Jinsheng**
*Chairman and Chief Executive Officer*

Hong Kong, December 3, 2025

*As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.*